Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel vs Bicalutamide in Metastatic Prostate Cancer
NCT01658527Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orteronel in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Clinical Progression-Free Survival. Planned start Jan 2014; status: withdrawn.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01658527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658527.